doc data software platform v2.0 (Doctor Evidence LLC)
90
Structured Review
Doctor Evidence LLC
doc data software platform v2.0
Doc Data Software Platform V2.0, supplied by Doctor Evidence LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/doc+tm+data+software+platform/doc+data+software+platform+v2+0/pm28673504-27-2-8
Average 90 stars, based on 1 article reviews
Doc Data Software Platform V2.0, supplied by Doctor Evidence LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/doc+tm+data+software+platform/doc+data+software+platform+v2+0/pm28673504-27-2-8
Average 90 stars, based on 1 article reviews
doc data software platform v2.0 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Software:Article Title: Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Article Snippet: ticle as: Farlow, n Neuropsychopha Abstract We evaluated the most current evidence regarding the benefits and harms of atypical antipsychotics in adults with dementia.. In June 2016, following a protocol developed a priori, we systematically searched several databases for published and unpublished data from randomized controlled trials (RCT), observational studies, and meta-analyses; conducted direct meta-analyses using a random effects model; and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.. One high-quality meta-analysis and published and unpublished data from 8 RCTs and 12 large observational studies met inclusion criteria. Article Title: Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis. Article Snippet: ) OR "secukinumab" [Supplementary Concept]) OR siltuximab[Title/Abstract]) OR "siltuximab" [Supplementary Concept]) OR "belimumab" [Supplementary Concept]) OR belimumab[Title/Abstract])))) NOT ((((((("Letter"[Publication Type]) OR "News"[Publication Type]) OR "Patient Education Handout"[Publication Type]) OR "Comment"[Publication Type]) OR "Editorial"[Publication Type])) OR "Newspaper Article"[Publication Type]))) NOT Article Title: Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction. Article Snippet: The quality of evidence regarding patient-centered outcomes in adults with heart failure (HF) after sacubitril combined with valsartan has not been systematically appraised.. We searched 4 databases in February 2017 and graded the quality of evidence according to the Grading of Control:Article Title: Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Article Snippet: ticle as: Farlow, n Neuropsychopha Abstract We evaluated the most current evidence regarding the benefits and harms of atypical antipsychotics in adults with dementia.. In June 2016, following a protocol developed a priori, we systematically searched several databases for published and unpublished data from randomized controlled trials (RCT), observational studies, and meta-analyses; conducted direct meta-analyses using a random effects model; and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.. One high-quality meta-analysis and published and unpublished data from 8 RCTs and 12 large observational studies met inclusion criteria. Article Title: Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis. Article Snippet: ) OR "secukinumab" [Supplementary Concept]) OR siltuximab[Title/Abstract]) OR "siltuximab" [Supplementary Concept]) OR "belimumab" [Supplementary Concept]) OR belimumab[Title/Abstract])))) NOT ((((((("Letter"[Publication Type]) OR "News"[Publication Type]) OR "Patient Education Handout"[Publication Type]) OR "Comment"[Publication Type]) OR "Editorial"[Publication Type])) OR "Newspaper Article"[Publication Type]))) NOT Article Title: Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction. Article Snippet: The quality of evidence regarding patient-centered outcomes in adults with heart failure (HF) after sacubitril combined with valsartan has not been systematically appraised.. We searched 4 databases in February 2017 and graded the quality of evidence according to the Grading of |